Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis

Abstract Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to inhibit lymphocyte trafficking to the intestine, but its broader effects on other cell subsets...

Full description

Bibliographic Details
Main Authors: Elvira Mennillo, Yang Joon Kim, Gyehyun Lee, Iulia Rusu, Ravi K. Patel, Leah C. Dorman, Emily Flynn, Stephanie Li, Jared L. Bain, Christopher Andersen, Arjun Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Madison L. Lotstein, Maha Rahim, Mohammad Naser, Faviola Bernard-Vazquez, Walter Eckalbar, Soo-jin Cho, Kendall Beck, Najwa El-Nachef, Sara Lewin, Daniel R. Selvig, Jonathan P. Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Pisco, Alexis J. Combes, Michael G. Kattah
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-45665-6